血清C反应蛋白作为肌萎缩侧索硬化的预后生物标志物
该研究在意大利三级多学科中心评估394例ALS患者的血清CRP水平,并在独立队列116例中验证。发现CRP与功能损害严重程度相关,且与生存期独立相关。事后分析提示基线CRP升高的患者接受高剂量NP001后功能损害更轻。
要点
- 血清CRP水平与ALS患者功能损害严重程度呈负相关。
- CRP升高与ALS患者生存期缩短独立相关。
- 基线CRP升高者接受高剂量NP001后功能损害改善更明显。
核心结论
- 血清CRP升高的ALS患者疾病进展更快,该升高可能反映神经炎症状态,并对免疫调节剂如NP001有潜在反应。
研究设计与样本
- 研究在2009年1月1日至2015年6月30日期间,于意大利三级多学科中心观察394例ALS患者(168女,226男;诊断时平均年龄60.18岁,SD=13.60),并在基于人群注册的独立队列116例ALS患者(50女,66男;诊断时平均年龄67.00岁,SD=10.74)中重复验证。
- 对NP001的2期试验进行事后分析,以确定按CRP水平分层是否能区分应答者与非应答者。
临床怎么用
- 血清CRP可作为ALS患者疾病进展和生存期的预后生物标志物,有助于识别进展更快的患者。
- 基线CRP水平可能用于筛选对免疫调节治疗(如NP001)潜在获益的ALS患者。
局限性
- 研究为观察性队列,CRP与预后的因果关系不能确定。
- NP001相关结果来自2期试验的事后分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Various factors have been proposed as possible candidates associated with the prognosis of amyotrophic lateral sclerosis (ALS); however, there is still no consensus on which biomarkers are reliable prognostic factors. C-reactive protein (CRP) is a biomarker of the inflammatory response that shows significant prognostic value for several diseases. OBJECTIVE: To examine the prognostic significance of CRP in ALS. DESIGN, SETTING, AND PARTICIPANTS: Patients' serum CRP levels were evaluated from January 1, 2009, to June 30, 2015, in a large cohort of patients with ALS observed by an Italian tertiary multidisciplinary center. Results were replicated in an independent cohort obtained from a population-based registry of patients with ALS. A post hoc analysis was performed of the phase 2 trial of NP001 to determine whether stratification by levels of CRP improves differentiation of responders and nonresponders to the drug. MAIN OUTCOMES AND MEASURES: Serum CRP levels from the first examination were recorded to assess their effect on disease progression and survival. RESULTS: A total of 394 patients with ALS (168 women and 226 men; mean [SD] age at diagnosis, 60.18 [13.60] years) were observed in a tertiary multidisciplinary center, and the analysis was replicated in an independent cohort of 116 patients with ALS (50 women and 66 men; mean [SD] age at diagnosis, 67.00 [10.74] years) identified through a regional population-based registry. Serum CRP levels in the 394 patients with ALS correlated with severity of functional impairment, as measured by total score on the ALS Functional Rating Scale-Revised, at first evaluation (r = -0.14818; P = .004), and with patient survival (hazard ratio, 1.129; 95% CI, 1.033-1.234; P = .007). Similar results were found in the independent cohort (hazard ratio, 1.044; 95% CI, 1.016-1.056; P ≤ .001). Moreover, a post hoc analysis of the phase 2 trial of NP001 using the same CRP threshold showed that patients with elevated baseline CRP levels receiving the higher dose of NP001 had significantly less functional impairment after the treatment period compared with patients with normal baseline CRP, regardless of whether patients with normal CRP levels received NP001 or placebo (3.00 [3.62] vs -7.31 [6.23]; P = .04). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with ALS and elevated serum CRP levels progress more rapidly than do those with lower CRP levels and that this elevation may reflect a neuroinflammatory state potentially responsive to the immune regulators such as NP001.
引用
- Lunetta C, Lizio A, Maestri E, et al. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017. PMID: 28384752. doi:10.1001/jamaneurol.2016.6179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。